Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda

Rogier, Eric; McCaffery, Jessica N.; Nace, Doug; Svigel, Samaly Souza; Assefa, Ashenafi; Hwang, Jimee; Kariuki, Simon; Samuels, Aaron M.; Westercamp, Nelli; Ratsimbasoa, Arsène; Randrianarivelojosia, Milijaona; Uwimana, Aline; Udhayakumar, Venkatachalam; Halsey, Eric S.

doi:10.3201/eid2803.211499

i

Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda

Supporting Files Public Domain

2022/03/01
By Rogier, Eric ; McCaffery, Jessica N. ; Nace, Doug
http://dx.doi.org/10.3201/eid2803.211499

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Rogier, Eric ; McCaffery, Jessica N. ; Nace, Doug ; Svigel, Samaly Souza ; Assefa, Ashenafi ; Hwang, Jimee ; Kariuki, Simon ; Samuels, Aaron M. ; Westercamp, Nelli ; Ratsimbasoa, Arsène ; Randrianarivelojosia, Milijaona ; Uwimana, Aline ; Udhayakumar, Venkatachalam ; Halsey, Eric S.
Description:

Histidine-rich protein 2 (HRP2)-based rapid diagnostic tests detect Plasmodium falciparum malaria and are used throughout sub-Saharan Africa. However, deletions in the pfhrp2 and related pfhrp3 (pfhrp2/3) genes threaten use of these tests. Therapeutic efficacy studies (TESs) enroll persons with symptomatic P. falciparum infection. We screened TES samples collected during 2016-2018 in Ethiopia, Kenya, Rwanda, and Madagascar for HRP2/3, pan-Plasmodium lactate dehydrogenase, and pan-Plasmodium aldolase antigen levels and selected samples with low levels of HRP2/3 for pfhrp2/3 genotyping. We observed deletion of pfhrp3 in samples from all countries except Kenya. Single-gene deletions in pfhrp2 were observed in 1.4% (95% CI 0.2%-4.8%) of Ethiopia samples and in 0.6% (95% CI 0.2%-1.6%) of Madagascar samples, and dual pfhrp2/3 deletions were noted in 2.0% (95% CI 0.4%-5.9%) of Ethiopia samples. Although this study was not powered for precise prevalence estimates, evaluating TES samples revealed a low prevalence of pfhrp2/3 deletions in most sites.
Subjects:
Source:

Emerg Infect Dis. 2022; 28(3):608-616
Pubmed ID:

35201739
Pubmed Central ID:

PMC8888236
Document Type:

Text
Genre:

Journal Article
Place as Subject:

Ethiopia ; Kenya ; Madagascar ; Rwanda
Volume:

28
Issue:

3
Download URL:

https://stacks.cdc.gov/view/cdc/115211/cdc_115211_DS1.pdf
File Type:

[PDF - 1.57 MB]
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha-512:dff6fc8d887d53141f5c4571ed7c43665c1f445edb3cb2298c83704103d3eb33a5c5845c8d2784271f08ea33221cc63c8015cb43fa409a8b97248ec8b1f2f80e

File Language:

English

ON THIS PAGE

Details Supporting Files

Was this page helpful?

Found an issue?

Send us an email at:

publishinghd@cdc.gov

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.